Intensive therapy and remissions in rheumatoid arthritis: a systematic review

Hughes, Catherine D.; Scott, David L.; Ibrahim, Fowzia

doi:10.1186/s12891-018-2302-5

BMC Musculoskeletal Disorders

Table 1 Details of Studies with Control Groups

From: Intensive therapy and remissions in rheumatoid arthritis: a systematic review

First Author	Study	Year	Design	Groups	RA Duration	Quality Assessments			Months Follow-up	Treatments
						Allocation	Blinding	Bias Analysis		Control	Intensive
Atsumi [28]	C-Opera	2016	RCT	2	Early	Low risk	Low risk	Low risk	12	MTX	Certolizumab/MTX
Bakker [29]	Camera II	2012	RCT	2	Early	Low risk	Low risk	Low risk	24	MTX	Prednisolone/MTX
Bijlsma [30]	U-Act-Early	2016	RCT	3	Early	Low risk	Low risk	Low risk	24	MTX	Tocilizumab/MTX
Breedveld [31]	Premier	2005	RCT	3	Early	Low risk	Low risk	Low risk	24	MTX	Adalimumab/MTX
Burmester [32]	Function	2015	RCT	4	Early	Unclear	Unclear	Low risk	12	MTX	Tocilizumab/MTX
Capell [33]	Mascot	2007	RCT	3	Est’lishd	Low risk	Low risk	Low risk	12	MTX or SZP	MTZ/SZP
Cohen [34]	Reflex	2006	RCT	2	Est’lishd	Low risk	Low risk	Low risk	6	MTX	Rituximab/MTX
Detert [35]	Hit Hard	2012	RCT	2	Early	Low risk	Low risk	Low risk	6	MTX	Adalimumab/MTX
Dougadas [36]	Act-Ray	2013	RCT	2	Est’lishd	Low risk	Low risk	Low risk	6	Tocilizumab	Tocilizumab/MTX
Emery [37]	Avert	2014	RCT	3	Early	Low risk	Low risk	Low risk	12	MTX	Abatacept/MTX
Emery [38]	Comet	2008	RCT	2	Early	Low risk	Low risk	Low risk	12	MTX	Etanercept/MTX
Emery [39]	Go Before	2009	RCT	4	Est’lishd	Low risk	Low risk	Low risk	6	MTX	Golimumab/MTX
Emery [40]	Radiate	2008	RCT	3	Est’lishd	Low risk	Low risk	Low risk	6	MTX	Tocilizumab/MTX
Emery [41]	Serene	2010	RCT	3	Est’lishd	Low risk	Low risk	Low risk	12	MTX	Rituximab/MTX
Emery [42]	C-Early	2017	RCT	2	Early	Low risk	Low risk	Low risk	12	MTX	Certolizumab/MTX
Genovese [43]	RA Beacon	2016	RCT	3	Est’lishd	Low risk	Low risk	Low risk	6	DMARD	Baracitinib/DMARDs
Genovese [44]	Toward	2008	RCT	2	Est’lishd	Low risk	Low risk	Low risk	6	DMARD	Tocilizumab/DMARD
Goekoop Ruitermann [45]	BeSt	2005	RCT	4	Early	Low risk	Low risk	Low risk	12	DMARDs	Infliximab/DMARDs or Combination DMARDs
Grigor [46]	Ticora	2004	RCT	2	Est’lishd	Low risk	Low risk	Low risk	18	Usual Care	Combination DMARDs
Hetland [47]	Cimestra	2006	RCT	2	Early^a	Unclear	Low risk	Low risk	12	MTX	MTX/Ciclosporin
Horslev Petersen [48]	Opera	2014	RCT	2	Early^a	Low risk	Low risk	Low risk	12	MTX	Adalimumab/MTX
Kavanaugh [49]	Optima	2013	RCT	2	Est’lishd	Low risk	Low risk	Low risk	6	MTX	Adalimumab/MTX
Kivitz [50]	Brevacta	2014	RCT	2	Est’lishd	Low risk	Low risk	Low risk	6	DMARD	Tocilizumab/DMARD
Klareskog [51]	Tempo	2004	RCT	3	Est’lishd	Low risk	Low risk	Low risk	6	MTX	Etanercept/MTX
Kremer [52]	–	2005	RCT	3	Est’lishd	Low risk	Low risk	Low risk	12	MTX	Abatacept/MTX
Kremer [53]	Lithe	2011	RCT	3	Est’lishd	Low risk	Low risk	Low risk	24	MTX	Tocilizumab/MTX
Kremer [54]	–	2012	RCT	7	Est’lishd	Low risk	unclear	Low risk	6	MTX	Tofacitinib/MTX
Kremer [55]	–	2013	RCT	4	Est’lishd	Low risk	Low risk	Low risk	6	DMARD	Tofacitinib/DMARD
Nam [56]	Empire	2014	RCT	2	Early^a	Low risk	Low risk	Low risk	12	MTX	Etanercept/MTX
Nam [57]	Idea	2014	RCT	2	Early	Low risk	Low risk	Low risk	18	MTX	MTX/infliximab
Schiff [58]	Attest	2007	RCT	3	Est’lishd	Low risk	Low risk	Low risk	12	MTX	Abatacept/MTX or Infliximab/MTX
Schipper [59]	–	2012	Quasi-Exp	2	Early	High risk	High risk	Indeterminate	12	Usual care	Tight control^b
Smolen [60]	Certain	2014	RCT	2	Est’lishd	Low risk	Low risk	Low risk	12	DMARD	Certolizumab/DMARD
Smolen [61]	Go After	2009	RCT	3	Est’lishd	Low risk	Low risk	Low risk	6	DMARD	Golimumab/DMARD
Smolen [62]	Option	2008	RCT	3	Est’lishd	Low risk	Low risk	Low risk	6	MTX	Tocilizumab/MTX
Smolen [63]	Rapid2	2008	RCT	4	Est’lishd	Low risk	Low risk	Low risk	6	MTX	Certolizumab/MTX
Soubrier [64]	Guepard	2009	RCT	2	Early^a	Low risk	High risk	Unclear	12	MTX	Adalimumab/MTX
St. Clair [65]	–	2004	RCT	3	Early	Low risk	Low risk	Low risk	12	MTX	Infliximab/MTX
Symmons [66]	Brosg	2006	RCT	2	Est’lishd	High risk	Low risk	Low risk	36	Symptomic	Combination DMARDs
Tak [67]	Image	2010	RCT	3	Early	Low risk	Low risk	Low risk	12	MTX	Rituximab/MTX
Takeuchi [68]	Hopeful-1	2014	RCT	2	Early	Low risk	Low risk	Low risk	6	MTX	Adalimumab/MTX
Taylor [69]	RA Beam	2017	RCT	3	Est’lishd	Low risk	Low risk	Low risk	6	MTX	Baracitinib/MTX or Adalimumab/MTX
van der Heijde [70]	Oral Scan	2013	RCT	3	Est’lishd	Low risk	Low risk	Low risk	6	MTX	MTX/Tofacitinib
Van Ejik [71]	Stream	2012	RCT	2	Early	Uncertain	Low risk	Low risk	24	Usual care	Intensive treatment
van Vollenhoven [72]	Oral Standard	2012	RCT	4	Est’lishd	Low risk	Low risk	Low risk	6	MTX	Tofacitinib/MTX or Adalimumab/MTX
Verstappen [73]	Camera	2007	Open label	2	Early	High risk	High risk	Indeterminate	24	Usual care	Combination DMARDs
Weinblatt [74]	Go Further	2013	RCT	2	Est’lishd	Low risk	Low risk	Low risk	6	MTX	Golimumab/MTX
Westhovens [75]	–	2009	RCT	2	Early	Low risk	Low risk	Low risk	12	MTX	Abatacept/MTX

a. These trials enrolled patients with disease durations no more than 6 months. b. In Schipper et al. study by 12 months 16% controls had combination DMARDs and 6% had TNF inhibitors; with intensive treatment 30% had combination DMARDs and 12% TNF inhibitors. The trial was classified as comparing combination DMARDs
Abbreviations: RCT Randomised controlled trial, Est’lishd Established, MTX Methotrexate, SZP Sulfasalazine, DMARD Disease modifying anti-rheumatic drugs

Back to article page

ISSN: 1471-2474

Contact us

Submission enquiries: bmcmusculoskeletaldisorders@biomedcentral.com
General enquiries: ORSupport@springernature.com